Introduction {#sec1-1}
============

Inoperable tracheobronchial malignant narrowing is increasingly managed with self-expanding metallic stents (SEMS).\[[@ref1][@ref2][@ref3]\] The stent is usually deployed under general anesthesia through an orotracheal tube or by transtracheal (in tracheostomized patients) access. However, laryngeal mask, laryngoscopy, and conscious sedation have been used to minimize patient discomfort time and procedure time.\[[@ref2][@ref4][@ref5][@ref6][@ref7]\] We describe three patients with severe malignant central airway narrowing managed by self-expandable nitinol stent placement through endonasal route with the help of a flexible bronchoscope and fluoroscopic guidance under local anesthesia.

Materials and Methods {#sec1-2}
=====================

Three men with inoperable malignant severe tracheal or bronchial stenosis were treated between October 2012 and March 2015 \[[Table 1](#T1){ref-type="table"}\]. CT studies available showed \>90% stenosis of trachea in patient no. 1 and 2 \[Figures [1A](#F1){ref-type="fig"} and [B](#F1){ref-type="fig"}, [2A](#F2){ref-type="fig"}\] and left bronchial narrowing of 60% in patient no. 3 \[Figure [3A](#F3){ref-type="fig"} and [F](#F3){ref-type="fig"}\]. The first two patients presented with significant dyspnea and stridor, while the third patient had the complaint of tracheoesophageal fistula but was not symptomatic for left bronchial narrowing \[[Figure 3B](#F3){ref-type="fig"}\]. However, this patient risked imminent left bronchial obstruction either due to disease progression or during esophageal stenting, as its radial force might further displace the infiltrating mass into the left bronchus. Therefore, left bronchial stenting prior to covered esophageal stent placement was planned. These procedures were approved by our institute review board and were performed in accordance with the ethical standards of our institute.

###### 

Summary of the patients who underwent transnasal tracheobronchial stenting with bronchoscopic and fluoroscopic guidance under local anesthesia

![](IJRI-26-103-g001)

![CT findings and steps of transnasal stent deployment in patient no. 1. (A) Contrast-enhanced CT axial image and (B) coronal CT reconstruction image with volume-rendered tracheal lumen shows severe tracheal narrowing due to a nodal mass from the right side just above the carina. (C) Transnasal introduction of bronchoscope in sitting position. (D) Fluoroscopic image of guidewire placement via bronchoscope. (E) Transnasal introduction of Comvi™ covered tracheal stent. Note the position of the proximal yellow marker (black arrow). (F) Radiograph of stent assembly in position just before deployment. (G) Radiographs showing fully deployed tracheal stent in antero-posterior and lateral views](IJRI-26-103-g002){#F1}

![(A and B) Tracheal stenting in high tracheal obstruction (patient no. 2). (A) Coronal CT reconstruction image showing upper tracheal narrowing due to an infiltrating paratracheal mass causing significant obstruction (white arrows). (B) Radiograph shows tracheal stent deployed across the obstruction. Note vocal cords indentations safely above the stent margin (white arrows)](IJRI-26-103-g003){#F2}

![(A-G) Stenting for left bronchial narrowing (patient no. 3). CT images taken before and after the procedure with radiographs and photographs of the procedure. (A) CT images show left bronchial infiltration of the esophageal mass and (B) associated tracheoesophageal fistula (open white arrow). (C) Photograph shows transnasal access of left bronchus with the guidewire through the right nostril and bronchoscope re-introduced through the left nostril. (D) Radiograph shows transnasal bronchoscope proximal to the undeployed stent in the left bronchus. (E) Post-procedure radiograph shows the left bronchial and esophageal stents. (F) Pre-treatment and (G) Post-treatment oblique CT reconstructions along the left bronchus for comparison, showing the severity and extent of left bronchial narrowing which is resolved after stenting](IJRI-26-103-g004){#F3}

Technique {#sec1-3}
=========

An informed consent was obtained prior to the procedure. The procedure was performed on a C-arm compatible OT table with monitoring of vitals. In patient no. 1, the procedure was done with the patient in sitting position due to severe dyspnea. The other two patients were treated in supine position. Pharyngeal mucosa was desensitized with aerosolized 4% lignocaine. Superior laryngeal nerve block was given to anesthetize the supraglottic larynx. Transtracheal 4% lignocaine was used for tracheal anesthesia and to inhibit cough. Flexible adult bronchoscope (Model 11001BN1; Storz, Tuttlingen, Germany) with a diameter of 5.2 mm and a working channel of 2.3 mm was introduced through a nostril to the site of narrowing and negotiated beyond the lesion \[Figure [1C](#F1){ref-type="fig"} and [D](#F1){ref-type="fig"}\]. A guidewire (J-tip 0.035″, 260 cm superstiff Amplatz guidewire (Cook, Bloomington, USA) was passed through the working channel of the bronchoscope across the stenosis up to a segmental bronchus under fluoroscopy (BV Endura mobile 9″ C-Arm; Philips, DA Best, The Netherlands) \[[Figure 1D](#F1){ref-type="fig"}\]. The bronchoscope was withdrawn carefully keeping the guidewire in place and re-introduced through the other nostril to monitor the stent deployment \[[Figure 3C](#F3){ref-type="fig"}\]. For tracheal stenosis, a Niti-S™ Comvi™ tracheobronchial self-expandable nitinol stent 20 mm × 60 mm with 18F delivery system (Taewoong Medical, Gyeonggi-do, Korea) was used \[Figures [1F](#F1){ref-type="fig"} and [G](#F1){ref-type="fig"}, [2B](#F2){ref-type="fig"}\]. This delivery device has a yellow marker at the proximal end of the stent to aid easy positioning without fluoroscopy. The yellow marker must be beyond the vocal cord to avoid accidental deployment at supraglottic or glottis level \[[Figure 1E](#F1){ref-type="fig"}\]. For left bronchial stenting, a 12 mm × 40 mm Maris Plus self-expandable nitinol stent (Medtronic, Minneapolis, USA) with 6F delivery system was used \[Figure [3D](#F3){ref-type="fig"}, [E](#F3){ref-type="fig"} and [G](#F3){ref-type="fig"}\]. All stents could be easily negotiated over the guidewire across the stricture under bronchoscopic and fluoroscopic guidance and deployed. No balloon dilatation was necessary. In patient no. 3, a covered self-expandable nitinol esophageal stent (Expanse, Indus Medical, Kolkata, India) was deployed transorally under fluoroscopic guidance to treat the tracheoesophageal fistula \[Figure [3E](#F3){ref-type="fig"} and [G](#F3){ref-type="fig"}\].

Results {#sec1-4}
=======

All procedures were technically successful. Immediate improvement in ventilation was noticed with disappearance of stridor following tracheal stenting. Esophageal stent placement after left bronchial stenting was uneventful. No stent migrations were observed.

Discussion {#sec1-5}
==========

Transnasal tracheobronchial interventions including bronchoscopic biopsies, lavage, balloon dilatation of tracheobronchial stenosis, and treatment of bronchobiliary fistula have been described;\[[@ref8]\] however, to our knowledge, successful tracheal stenting through the nasal route has not been described earlier. Transnasal bronchoscopy is better tolerated then a transoral procedure. No prior intubation or general anesthesia is necessary, thereby significantly shortening the procedure time.\[[@ref8][@ref9]\] Smaller diameter fiber-optic bronchoscopes and smaller profile flexible stent introducer system have enabled us to perform these procedures in a quick and safe manner. In our institute, all adult bronchoscopies are done through transnasal route. Maximum diameter of covered Comvi tracheobronchial stent delivery system is 6 mm (18F), which is similar to most bronchoscopes, ultrathin endoscopes (4.9--6 mm),\[[@ref10]\] and wide bore nasogastric tubes (up to 20F, 6.67 mm; Romsons Scientific, Agra, India) for transnasal use. Easy transnasal passage of our flexible bronchoscope, which has a diameter of 5.2 mm, ensured easy navigation of the 6 mm (18F) delivery device. A failed attempt to deploy tracheal stent transnasally has been described possibly due to a larger delivery system (9 mm, 27F) of 20 mm × 40 mm Ultraflex™ tracheal stent.\[[@ref11]\] One possible limitation of our technique includes any significant obstruction in the nasal cavity including deviated nasal septum, nasal polyp, etc. In unilateral obstruction such as deviated nasal septum, initial access can be made through the other nostril for bronchoscopy followed by stent deployment, while bronchoscopic monitoring can be done via transoral access without any other modification. A variety of self-expandable stents are available to treat airway narrowing, the most common being wallstent and ultraflex stents (Boston Scientific, Marlborough, MA, USA).\[[@ref1][@ref2][@ref3][@ref4][@ref5][@ref6][@ref7][@ref11]\] Despite their limitations, silicone stents are also used by bronchoscopists, especially for benign diseases, and they require direct bronchoscopy under general anesthesia for deployment.\[[@ref4][@ref12]\] Choice depends largely upon expertise, user preference, availability, and patient-specific requirements.

Tracheobronchial stenting is performed using various techniques utilizing a flexible or rigid endoscope often under general anesthesia\[[@ref1][@ref13][@ref14]\] with endotracheal intubation or laryngeal mask.\[[@ref7]\] Veno-venous extracorporeal membrane oxygenation (VV ECMO) has also been used for critical stenoses.\[[@ref15]\] Others have described the procedure under conscious sedation and local anesthesia with either fluoroscopic\[[@ref2][@ref3]\] or bronchoscopic guidance.\[[@ref16]\] We consider fluoroscopic guidance absolutely necessary for accurate self-expandable nitinol airway stent placement.

Performing the procedure through the nasal route is convenient for the patient and easier for the therapist to manipulate the instruments even in awake patients. In addition, oral route is kept free for any anesthetic intervention during the procedure.

Conclusion {#sec1-6}
==========

To conclude, tracheobronchial stenting using self-expandable nitinol stent through transnasal route is safe. simple, straightforward, and least traumatic to the patient.
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